Study guide
11.3 Nonanalytic Classes of Case (30–49, 99) & Why Central Registries Need Them
NCRA Oncology Data Specialist ODS-C
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The ODS-C Exam, the Oncology Data Specialist Profession & Standard Setters
1.1 ODS Exam Structure, Timing, Scoring & 2026 Testing Windows 1.2 From CTR to ODS: The Credential, Eligibility Routes & the Registrar's Role 1.3 Standard-Setting Organizations & the Manuals They Publish
2 Chapter 2: Legal Framework, HIPAA & State Reporting Laws
2.1 HIPAA Privacy Rule & the Public Health Reporting Exception 2.2 HIPAA Security Rule, Safeguards & Breach Notification 2.3 State Mandatory Cancer Reporting Laws & Statutory Authority
3 Chapter 3: Confidentiality, Release of Information, Ethics & Credential Maintenance
3.1 Patient Confidentiality Protocols & Data Access Policies 3.2 Handling Subpoenas, Discovery & Registry Immunity Statutes 3.3 NCRA Code of Ethics & ODS Credential Maintenance
4 Chapter 4: Registry Organization, Staffing & Information Systems
4.1 Types of Cancer Registries, Their Functions & Registry Operating Protocols 4.2 Registry Staffing Formulas, Time Studies & Resource Allocation 4.3 Electronic Registry Systems, Security & Disaster Recovery Planning
5 Chapter 5: Cancer Committee, Cancer Conferences & Quality Improvement
5.1 The Cancer Committee: CoC Standards 2.1–2.4, the CLP & Annual Program Activities 5.2 Multidisciplinary Cancer Case Conferences (CoC Standard 2.5) 5.3 Quality Improvement Principles & CoC Chapter 7 (Standards 7.1–7.3)
6 Chapter 6: CoC Accreditation Standards, NCDB & Data Quality
6.1 CoC Accreditation: Standards Structure, Program Categories & Accreditation Awards 6.2 The National Cancer Database (NCDB), RCRS Submission & CoC Quality Measures 6.3 Quality Control Plans & Audit Techniques (CoC Standard 6.1)
7 Chapter 7: Surveillance Programs, NAACCR Standards, Epidemiology & Statistics
7.1 National Cancer Surveillance Programs: SEER & CDC NPCR 7.2 NAACCR Data Exchange Standards, XML Data Specifications & Registry Certification 7.3 Basic Cancer Epidemiology & Descriptive Statistics 7.4 Basic Statistics: Frequency Distributions, Central Tendency, Risk Ratios & Odds Ratios 7.5 Survival Analysis, Life Tables & Presentation of Registry Data
8 Chapter 8: Medical Terminology, Anatomy & Types of Cancer
8.1 Medical Terminology & Standard Abbreviations for Cancer Abstracting 8.2 Human Anatomy & Physiology for Registrars: Tissues, Organ Walls, Subsites & Lymphatic Drainage 8.3 Types & Characteristics of Cancer: Benign vs. Malignant, Tumor Families, Spread & Precursors
9 Chapter 9: Casefinding & Reportability
9.1 Principles of Casefinding & Facility Reference Dates 9.2 Casefinding Sources: Pathology, Cytology, Disease Index & Logs 9.3 Reportability: What CoC, SEER and NPCR Require, Including Non-Malignant CNS Tumors 9.4 Ambiguous Terminology: Reportable Terms, Cytology, Discrepancies & "References of Last Resort"
10 Chapter 10: Diagnostic Procedures, Pathology Reporting, Lab Methods & Prognostic Indicators
10.1 Diagnostic & Staging Procedures: Imaging, Endoscopy, Biopsy & How They Are Coded 10.2 Pathology Reporting, CAP Cancer Protocols & Electronic Pathology (CoC Standard 5.1) 10.3 Specialty Laboratory Testing Methods: IHC, FISH, PCR/RT-PCR, NGS, Flow Cytometry & Cytogenetics 10.4 Prognostic Indicators & Site-Specific Data Items (SSDIs): HPV, KRAS, HER2 and More
11 Chapter 11: Class of Case, Key Dates & Case Identifiers
11.1 Class of Case, Date of First Contact, Date of Diagnosis & Accession/Sequence Numbers 11.2 Analytic Classes of Case (00, 10–14, 20–22): Definitions & Decision Rules 11.3 Nonanalytic Classes of Case (30–49, 99) & Why Central Registries Need Them
12 Chapter 12: Follow-Up, Vital Status & Recurrence
12.1 Follow-Up Purpose, Active & Passive Methods, and Follow-Up Source Codes 12.2 CoC Standard 6.5 Follow-Up Rates: Windows, Exclusions & Calculations 12.3 Vital Status, Date of Last Contact, Cancer Status & Death Clearance 12.4 Recurrence: Type of First Recurrence [1880], Date of First Recurrence [1860] & Recurrence vs. New Primary
13 Chapter 13: Abstracting, ICD-O-3.2 Site & Histology Coding, and Grade
13.1 The Abstracting Process: Workflow, Source Documents, Timeliness & Text Documentation 13.2 ICD-O-3.2 Topography, Primary Site Rules & Laterality 13.3 ICD-O-3.2 Morphology: Histology, Behavior & the Solid Tumor Histology Rules 13.4 Grade: The Four Time-Specific Grade Items & Site-Specific Grade Tables
14 Chapter 14: Solid Tumor Rules & Hematopoietic Coding Rules
14.1 Solid Tumor Rules: Purpose, Site Groups, Navigation & Timing Principles 14.2 Solid Tumor Rules for Breast, Colon/Rectum & Lung: The Multiple Primary Rules in Order 14.3 Solid Tumor Rules for Head & Neck, Kidney, Urinary, CNS, Melanoma & Other Sites 14.4 Hematopoietic & Lymphoid Neoplasms: Heme Manual, Heme DB, Multiple Primary & Primary Site Rules
15 Chapter 15: Staging: AJCC TNM (8th Edition & Version 9 Lung) and Summary Stage 2018
15.1 AJCC TNM Principles: Categories, Prefixes, Suffixes, General Rules & Registry Items 15.2 AJCC Time Frames: Clinical, Pathological, Post-Therapy (yc, yp), Recurrence & Autopsy 15.3 Breast Staging (AJCC 8th Edition, Part XI): T, N, M, Anatomic & Prognostic Stage Groups 15.4 Lung Staging (AJCC Version 9, 2025+): T, N2a/N2b, M1c1/M1c2 & New Stage Groups 15.5 Male Genital & Urinary Tract Staging (AJCC 8th Parts XIII–XIV): Prostate, Testis, Kidney, Bladder, Renal Pelvis & Ureter 15.6 SEER Summary Stage 2018: Codes, Timing, General Rules & Site Examples
16 Chapter 16: First-Course Treatment Coding (STORE 2025) & EDITS
16.1 Treatment Types, First Course of Treatment & Evidence-Based Guidelines (NCCN) 16.2 Surgery Coding: Rx Summ–Surg 2023 [1291], Lymph Node Surgery [1292], Other Site [1294], Margins & Reason for No Surgery 16.3 Radiation, Systemic, Transplant, Other & Palliative Treatment Coding (STORE 2025) 16.4 NAACCR EDITS, Over-ride Flags & Data Validation
11.3 Nonanalytic Classes of Case (30–49, 99) & Why Central Registries Need Them
Key Takeaways Explain This Topic AI
Codes 30–33 cover patients diagnosed and fully treated elsewhere who came to the facility for a workup or consult (30), in-transit care (31), recurrence or persistence (32), or with disease history only (33).
Codes 34 and 36 cover tumor types CoC does not require (for example, benign non-CNS tumors, CIN III, PIN III) diagnosed at the facility (34) or elsewhere (36); codes 35 and 37 cover cases diagnosed before the program's reference date, at the facility (35) or elsewhere (37).
Class 38 is a diagnosis first established by autopsy at the reporting facility when cancer was not suspected before death, and Class 49 is death certificate only.
Codes 40–43 are for patients who never appeared in person: one staff physician's office (40), two or more staff physicians' offices (41), a non-staff physician or unaccredited facility abstracted by the hospital (42), and pathology or other lab specimens only (43).
Class 99 is a nonanalytic case with unknown relationship to the facility and is not to be used by CoC-accredited programs for analytic cases.
Last updated: September 2026
Where nonanalytic cases fit
CoC does not require accredited programs to accession, abstract or follow nonanalytic cases, and they are not part of routine treatment or survival statistics. They are still collected when:
The state or regional central registry requires them. Most states require every facility to report every reportable cancer it sees, whatever the Class of Case.
The cancer committee asks for them, for example Class 30 cases to measure referral volume. STORE lists this as a reason to accession nonanalytic cases.
The facility wants a complete patient history , for example to assign correct sequence numbers.
Patient appears in person at the reporting facility (30–38)
Code STORE definition Typical example
30 Initial diagnosis and all first-course treatment elsewhere, and the facility participated in the diagnostic workup, such as consult only, treatment plan only, or a staging workup after diagnosis elsewhere A second-opinion visit where the tumor board reviews the case and the patient goes home for treatment
31 Initial diagnosis and all first-course treatment elsewhere, and the facility gave in-transit care, or care that helped treatment elsewhere (for example, stent placement) Chemotherapy while visiting for a family wedding, then return to the original hospital; monitoring of an oral drug started elsewhere
32 Diagnosis and all first-course treatment elsewhere, and the patient comes with recurrence or persistence (active disease) Admission for supportive care after treatment failure
33 Diagnosis and all first-course treatment elsewhere, and the patient comes with disease history only (no active disease) A patient with a past lymphoma admitted for a hip replacement
34 Tumor type not required by CoC , and initial diagnosis and part or all of first-course treatment at the facility A benign colon tumor; cervical CIN III or PIN III diagnosed and treated at the facility
35 Diagnosed before the program's reference date , with initial diagnosis and all or part of first-course treatment at the facility A 2008 case at a program whose reference date is 2010
36 Tumor type not required by CoC, with initial diagnosis elsewhere and all or part of first-course treatment at the facility A benign non-CNS tumor diagnosed elsewhere and treated at the facility
37 Diagnosed before the reference date, with initial diagnosis elsewhere and all or part of first-course treatment at the facility A pre-reference-date case diagnosed elsewhere
38 Initial diagnosis established by autopsy at the facility, and cancer was not suspected before death An incidental renal cell carcinoma found at autopsy
STORE assigns 34 or 36 to:
Benign or borderline tumors (behavior 0 or 1) diagnosed before 2004 at any site.
Benign or borderline tumors diagnosed in 2004 or later at any site other than the brain and CNS sites: meninges, brain, spinal cord, cranial nerves and other CNS, pituitary, craniopharyngeal duct and pineal gland.
Cervical CIS and intraepithelial neoplasia grade III of the cervix (CIN III), prostate (PIN III), vulva (VIN III), vagina (VAIN III) and anus (AIN III), coded 8077/2 or 8148/2.
Patient does not appear in person (40–49)
- Code STORE definition
- 40 Diagnosis and all first-course treatment given in the same staff physician's office
41 Diagnosis and all first-course treatment given in two or more different offices of physicians with admitting privileges
42 Non-staff physician, or non-CoC-accredited clinic or other facility that is not part of the reporting facility, accessioned by the reporting facility (for example, an independent radiation facility, or a free-standing clinic the hospital abstracts voluntarily)
- 43 Pathology or other lab specimens only
- 49 Death certificate only
- 99 Nonanalytic case of unknown relationship to the facility (not for CoC-accredited programs' analytic cases)
- Boundaries that exam items test
Class 32 versus a new primary. A patient treated elsewhere who comes to your facility with recurrence is Class 32. If the Solid Tumor Rules make the new tumor a new primary diagnosed at your facility, that tumor gets its own analytic Class of Case.
Class 30 becoming analytic. If a consult-only patient returns for any first-course treatment, change the code to 20, 21 or 22, and update Date of First Contact.
Class 43 becoming analytic. If a pathology-only patient later receives first-course treatment at the facility, update both the Class of Case and Date of First Contact to the first in-person contact.
Class 38 versus analytic. If cancer was suspected before death and the autopsy confirmed it, the diagnosis was not first established at autopsy. Code the case by where it was suspected, diagnosed and treated.
Class 38 and 49 dates. The date of diagnosis is the date of death for Class 38 and Class 49 cases.
In-transit (31) versus continued first course (21). Temporary care away from home is 31. Moving care to your facility for the rest of the planned first course is 21.
Central registry uses of nonanalytic reports
Central registries need every reportable tumor in their population, whoever diagnosed it. Nonanalytic reports help them:
Complete incidence counts, because physician-office (40–41), independent-facility (42) and pathology-only (43) cases may be the only source for a tumor.
Consolidate multiple reports of the same tumor into a single record, resolving conflicts between facilities.
Perform death clearance , which is matching death certificates that mention cancer against the registry. Unmatched deaths are followed back to the certifier or the facility. Only tumors that stay unresolved after follow-back remain death certificate only (DCO) cases, which NAACCR limits to 3% or less for Gold certification.
Update follow-up and vital status , because a Class 32 or 33 admission shows the patient was alive on that date.